202 related articles for article (PubMed ID: 18791116)
1. Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?
Chavez-Tapia NC; Tiribelli C
Gut; 2008 Oct; 57(10):1351-3. PubMed ID: 18791116
[No Abstract] [Full Text] [Related]
2. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
[TBL] [Abstract][Full Text] [Related]
3. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
Adams LA; George J; Bugianesi E; Rossi E; De Boer WB; van der Poorten D; Ching HL; Bulsara M; Jeffrey GP
J Gastroenterol Hepatol; 2011 Oct; 26(10):1536-43. PubMed ID: 21950746
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.
Calès P; Boursier J; Chaigneau J; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Cavaro-Ménard C; Gallois Y; Deugnier Y; Rousselet MC
Liver Int; 2010 Oct; 30(9):1346-54. PubMed ID: 20666992
[TBL] [Abstract][Full Text] [Related]
5. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.
Manousou P; Kalambokis G; Grillo F; Watkins J; Xirouchakis E; Pleguezuelo M; Leandro G; Arvaniti V; Germani G; Patch D; Calvaruso V; Mikhailidis DP; Dhillon AP; Burroughs AK
Liver Int; 2011 May; 31(5):730-9. PubMed ID: 21457446
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive assessment of fibrosis and steatosis in NASH and ASH.
Angulo P
Gastroenterol Clin Biol; 2009; 33(10-11):940-8. PubMed ID: 19800187
[TBL] [Abstract][Full Text] [Related]
7. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis.
Iacobellis A; Mangia A; Leandro G; Clemente R; Festa V; Attino V; Ricciardi R; Giacobbe A; Facciorusso D; Andriulli A
Am J Gastroenterol; 2005 Apr; 100(4):868-73. PubMed ID: 15784034
[No Abstract] [Full Text] [Related]
8. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease.
Ruffillo G; Fassio E; Alvarez E; Landeira G; Longo C; Domínguez N; Gualano G
J Hepatol; 2011 Jan; 54(1):160-3. PubMed ID: 20934232
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
Wieckowska A; McCullough AJ; Feldstein AE
Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
[TBL] [Abstract][Full Text] [Related]
10. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease.
Cerović I; Mladenović D; Ješić R; Naumović T; Branković M; Vučević D; Aleksić V; Radosavljević T
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):899-904. PubMed ID: 23426271
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
12. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?
Yu AS; Keeffe EB
Am J Gastroenterol; 2003 May; 98(5):955-6. PubMed ID: 12809814
[No Abstract] [Full Text] [Related]
13. [Interpretation of hypertransaminasemia].
Othmani S; Bahri M; Bahri M
Tunis Med; 2002 May; 80(5):236-44. PubMed ID: 12534025
[TBL] [Abstract][Full Text] [Related]
14. [The serum gamma-glutamyltranspeptidase level in clinical diagnosis (author's transl)].
Mayr K
Wien Klin Wochenschr; 1973 Feb; 85(6):83-7. PubMed ID: 4155171
[No Abstract] [Full Text] [Related]
15. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
[TBL] [Abstract][Full Text] [Related]
16. [Non-invasive markers of esophageal varices in compensated liver cirrhosis].
Arhip O; Cijevschi-Prelipcean C; Manole A; Merchez M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):64-9. PubMed ID: 21688561
[TBL] [Abstract][Full Text] [Related]
17. [Information value of 2 color tests in the determination of alanine and aspartate-aminotransferases in liver and biliary tract diseases].
Kunz I; Hölzel D; Seidel R; Hölzel W
Z Gesamte Inn Med; 1975 Aug; 30(16):555-6. PubMed ID: 1189510
[TBL] [Abstract][Full Text] [Related]
18. Diabetic fatty liver disease is associated with specific changes in blood-borne markers.
Sharma S; Barrett F; Adamson J; Todd A; Megson IL; Zentler-Munro PL; MacRury SM
Diabetes Metab Res Rev; 2012 May; 28(4):343-8. PubMed ID: 22576780
[TBL] [Abstract][Full Text] [Related]
19. [Non-alcoholic fatty liver].
Zwimpfer J
Praxis (Bern 1994); 2000 Oct; 89(43):1757-8. PubMed ID: 11103621
[No Abstract] [Full Text] [Related]
20. The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
Myara A; Guechot J; Lasnier E; Imbert-Bismut F; Voitot H; Ferard G
Hepatology; 2008 Mar; 47(3):1100-1. PubMed ID: 18266251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
